Bausch+Lomb
investigational first in class treatment for dry eye disease associated with gland dysfunction | Bausch+Lomb
Company
Deck Type
Sector
Industry
Deck date
June 2022
Slide
19 of 41
Related slides by other companies
BenevolentAI
Investor Presentation
October 2022
ben phase progressing phase double blind placebo controlled in patient two part clinical study day day day day active recruiting sites in the in a further sites under approval recruitment completion anticipated our intention is to to partner this asset with a pharmaceutical company that has a focus in dermatology for continued clinical development and if approved our intention is to out development and of ben following completion of this trial with key big and dermatology specialists as potential part | BenevolentAI
Recursion Pharmaceuticals
Investor Day
January 2023
clinical phase studies well tolerated with no dose dependent adverse events in sad and mad mad study placebo further confidence confirming safety | Recursion Pharmaceuticals
ATAI
Investor Presentation
January 2024
core study weeks phase a is an open label in patients | ATAI
Ocuphire Pharma
Results
January 2023
zeta scores study and fellow eye | Ocuphire Pharma
Other recent decks by Bausch+Lomb
See all presentations (10 decks)
Results
February 2024
Results
October 2023
Results
August 2023
Results
May 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights